After-Hours Movers: AMAT, DLO, GLOB, YSS, ETON
Investing.com’s after-hours roundup cites moves in AMAT, DLO, GLOB, YSS, and ETON. AMAT fell 4% after a fiscal Q3 beat and raised Q4 revenue guidance. DLO slipped 3.5% on a slight EPS miss despite revenue upside. GLOB dropped 16% after missing earnings and cutting 2026 guidance. YSS fell 22% on weak Q2 and sharply reduced 2026 forecast. ETON rose 25% after strong Q2 results and a major 2026 guidance increase.
How this was made
The 30-second read
Why it matters
Traders can use the guidance direction and stated drivers (FX/margins, enterprise spending, contract execution delays, adoption acceleration) to update near-term estimate risk and positioning for the next earnings cycle.
Market read
The dominant actionable signal is guidance direction versus consensus, which explains the magnitude and sign of after-hours moves across multiple sectors.
What to watch
The article does not detail balance-sheet strength, backlog, or contract award pipeline for YSS, nor does it quantify FX hedging or cost actions for DLO, which could change the forward earnings trajectory.
Background
The piece is an after-hours roundup explaining large single-name moves tied to quarterly results and guidance changes, alongside a broader market note about rate-hike bets easing after PPI.
Ticker impact
Applied Materials dipped 4% after its fiscal Q3 beat-and-raise, despite Q4 revenue guidance topping consensus, triggering sell-the-news profit-taking.
Choppy to slightly negative near term; direction depends on whether guidance is re-rated higher after the initial profit-taking.
The article attributes the drop to expectations and short-term profit-taking, not a deterioration in fundamentals.
DLocal fell 3.5% after Q2 EPS missed consensus, even as revenue beat, with FX headwinds and emerging-market margin compression cited.
Further volatility to the downside is plausible if FX and margin compression persist.
The text directly links the stock drop to EPS miss plus FX and margin compression, which are concrete drivers for future earnings.
Globant plunged 16% after missing Q2 EPS and cutting forward outlook, including 2026 revenue guidance below expectations.
Sustained weakness risk until the company provides a clearer path to re-accelerating enterprise spending.
The article specifies both the EPS miss and the downbeat full-year 2026 revenue guidance versus consensus.
York Space Systems cratered 22% after a Q2 loss and a sharp full-year 2026 revenue forecast cut tied to government contract execution delays.
Downward bias until contract execution timing improves or new awards/updates emerge.
The guidance reduction and the stated reason (execution delays) are explicit, but the magnitude of future recovery is not quantified.
Eton Pharmaceuticals surged 25% after a blowout Q2 and a major full-year 2026 revenue guidance raise to more than $145 million.
Momentum support likely near term, with upside follow-through if adoption trends continue.
The article provides concrete upside surprises: EPS beat, revenue beat, and a raised full-year target above consensus.
Market effects
Semiconductor equipment and IT services show expectation-sensitive post-earnings reactions; payments and satellite/defense highlight execution and margin risks; rare disease pharma shows guidance-driven momentum.
No specific regional transmission beyond sector sentiment implied by the after-hours moves.
Cross-border payments weakness reflects broader FX and emerging-market margin pressures; satellite revenue visibility tied to government execution timelines.
Counterpoint
Some declines (notably AMAT) may be overdone if guidance is genuinely above consensus and the sell-the-news move fades with analyst revisions.
Key entities
- public_companyApplied Materials
Fiscal Q3 beat-and-raise with Q4 guidance above consensus, yet shares fell on sell-the-news expectations.
- public_companyDLocal Limited
Q2 EPS slightly missed while revenue beat; FX headwinds and emerging-market margin compression weighed on sentiment.
- public_companyGlobant
Q2 EPS miss and reduced forward outlook, including 2026 revenue guidance below expectations.
- public_companyYork Space Systems
Q2 loss and sharp full-year revenue forecast cut due to government contract execution delays.
- public_companyEton Pharmaceuticals
Q2 blowout and major full-year revenue guidance raise, supported by accelerating adoption.
